Pharma Journalist

Multiscale and multi-modal insights into drug formulation
2021-09-07 | Webinar | 15pm BST
SMi Group are delighted to introduce a free exclusive webinar taking place on 7th September 2021 at 3pm BST, hosted by Zeiss.
Synopsis / Webinar Overview:
The majority of pharmaceutical powders require a size <500 μm for ease of manufacture and biopharmaceutical performance. Powder behaviour of particles in this size-range spans cohesive to aeratable powders. Powder performance is dependent on the powder bulk density and micromeritic properties of individual particles, but also crucially the structuring of particles within the powder bed. Micromeritic assessment is also routinely performed using image analysis or particle sizing techniques such as laser diffraction analysis. However, there is a clear need for techniques that provide non-destructive granular information of pharmaceutical powder structures.
Formulation equivalence between different batches of products or between comparator innovator and generic products has emerged as a hot topic of consideration in regulatory science. Microstructural equivalence (Q3) for powder products is complex, and particularly in the case of Dry Powder Inhalation (DPI) formulations. It is in the characterization of the bulk powder that microstructural assessment is a particular challenge. Current methods for measuring critical material attributes such as the particle size and shape suffer from low resolution, image in 2D or make shape assumptions.
In this webinar, we will present some new approaches using X ray Microscopy (XRM) from nano- to micro-scale that can be utilized for characterizing inhalation powder blends non-destructively to obtain fully 3D information on particle size and shape, its distributions, and powder bed packing. Novel methodologies developed to identify individual chemical phases within blends, their crystal orientations and interactions in 3D will also be presented. The results show the promise for XRM as a valuable powder characterisation technique that develops our fundamental understanding of powder microstructure, and microstructural descriptors for the United States Food and Drug Administration Q3 microstructural assessments.
Register your free place: http://www.drug-formulation-zeiss-webinar.com/pjwl
Who will be speaking?
Dr Hrishikesh Bale – Marketing Solutions Manager, Engineering Materials
Carl Zeiss – Research Microscopy Solutions
Key Takeaways
In this webinar you will learn:

About the importance of pharmaceutical powder microstructure and the current landscape of the methods for microstructural characterization
How X-ray Microscopy (XRM) can provide information on key microstructrual metrics, as well as the interaction between formulation components
How the unique microstructural insight provided by XRM can help understand powder performance
About a range of applications of XRM to pharmaceutical powders, including powder beds and complex inhalation formulations

Register your free place: http://www.drug-formulation-zeiss-webinar.com/pjwl
Who is this webinar aimed at?
This interactive webinar is designed for all users, from both academic and industrial sectors, who are interested in powder characterisation. The webinar is suitable for both a technical and non-technical audience and will provide insight into applications of XRM as a microstructural characterisation technique.
Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk

Pre-filled Syringes San Francisco 2021
2021-09-13 - 2021-09-14 | Hyatt Centric Fisherman’s Wharf, San Francisco (Virtual Attendance Option Available)
As part of SMi’s leading Injectables series, this year’s event will address the key drivers of the pre-filled syringes and combination products industry to give a comprehensive insight into the latest device innovations, regulatory updates and future insights for the coming year. With the global market for prefilled syringes estimated to exceed $9.7bn by 2025, the field is evolving at an exponential rate with connectivity and digital health strategies for devices and studies at the forefront. Furthermore, this event will delve into the key takeaways following the global pandemic and discover how this will be used to enhance future drug delivery device development.
This comprehensive overview will explore the changing global market and latest innovations in device design and development for injectable drug delivery. Case studies from leading industry and regulatory experts will explore platform approaches for combination products, enhanced device design and usability considerations, change management and compatibility for novel drug products.
The two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.
Plus, two interactive post conference workshops:
A: Connected Devices and Digital Health: How to Navigate the U.S. FDA Usability Engineering Requirements
Workshop Leader: Shannon Clark, CEO, UserWise
B: Postmarket Safety Reporting: The Current Regulatory Environment with a Global Impact
Workshop Leader: Khaudeja Bano, Executive Medical Director, Combination Product Safety Head, Amgen
Benefits of attending:

Engage in case studies from big pharma leading experts on smart devices and connected delivery to aid the user experience
Explore evolving device design and innovations for high volume and high viscous delivery
Delve into regulatory updates on device development and human factors with insights from industry and regulatory bodies
Uncover how industry is incorporating risk management and controls into early stages for a holistic development process

Chairs for 2021:

Shannon Clark, CEO, UserWise
Paul Upham, Head Smart Devices, Roche/Genentech

Featured 2021 speakers include:

Alan M. Stevens, Acting Director – Division of Drug Delivery, General Hospital, and Human Factors, CDRH, FDA
George Cusatis, Director, Regulatory Affairs, Merck
James Robert Wise, Associate Senior Consultant Engineer, Eli Lilly
Jim Leamon, Director of Biologics Device Development, Jazz Pharmaceuticals
Scott Surrette, Manager Combination Product Development, Regeneron
Jace Blackburn, Smart Device Engineer, Roche/Genentech
Alasdair Young, Senior Director, Device Engineering, Coherus BioSciences
Rachel Poker, Human Factors Engineering Manager, Device Development, AstraZeneca
Young Chun, Associate Director – Lead Human Factors and User Research, R&D/Medical Devices Center of Excellence, Takeda
Mehak Mehta, Scientist II, Protein Drug Product Development, Biogen
Alie Jahangir, Sr. Principle Engineer, Combination Products and Emerging Technologies, Janssen Pharmaceuticals
Sindhuja Kuchibhatla, Device Development Engineer, New Technologies Management, Regeneron Pharmaceuticals

EARLY-BIRD RATES:

BOOK BY 28TH MAY AND SAVE £200
BOOK BY 30TH JUNE AND SAVE £100

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
LinkedIn: @SMi Pharma
Twitter: #smipfsusa

Gene Therapy for Metabolic Disorders
2021-09-14 - 2021-09-16 | Digital Event | EDT
More companies and institutions than ever before are embarking on development of gene therapies in metabolic disease, and they are encountering unique challenges, from fine-tuning dosing to defining clinically relevant biomarkers. Gene Therapy for Metabolic Disorders will unite large pharma and innovative biotechs to collectively overcome translational drug development barriers to deliver on the transformative promise of gene therapy approaches for patients in need.
Incorporating in-depth insights into the leading metabolic disease programs, this event will ensure that you can optimize dosing to achieve the required enzyme levels without over-expression, define the necessary parameters for transitioning to first-in-human trials, and overcome unique challenges encountered in multi-organ systemic gene therapy delivery for complex metabolic indications.
Don’t get left behind. Join colleagues from Preclinical, Translational and Clinical departments of leading companies including AVROBIO, Freeline Therapeutics and LogicBio to optimize your gene therapy approach and revolutionize the treatment of metabolic diseases.
To know more about Gene Therapy for Metabolic Disorders please click here.

CRISPR 2.0 Summit
2021-09-16 - 2021-09-18 | Digital Event
In the time since its discovery, CRISPR has rapidly become an established tool in the genomics toolbox. Now the question is: What next?
The CRISPR 2.0 Summit is devoted to showcasing only the latest and greatest innovations by uncovering how the next generation of CRISPR tools are radically enhancing efficacy, minimizing off-target effects & enabling efficient delivery to specific tissues to ensure you stay at the forefront of this rapidly exploding field.

Discover the promise of novel Cas variants, base and prime editing approaches, innovative delivery mechanisms, and the applications of these next generation tools through learnings from CRISPR clinical trials and new & unpublished data.
Don’t get left behind. Join 100+ leading pharma and biotech companies pioneering CRISPR-based therapeutics into the clinic to usher in the next generation of safe, targeted and effective genome editing.
Rather than attending yet another CRISPR meeting that covers old ground, CRISPR 2.0 will offer you the opportunity to:

Discuss methods to overcome CRISPR delivery challenges and delve into the latest delivery platforms with innovative work on the developments of viral and non-viral candidates suitable for ex-vivo and in-vivo delivery with Scribe Therapeutics and AskBio
Explore the potential of novel prime and base editing, improving on editing accuracy. Hear directly from Andrew Anzalone, the pioneer that developed prime editing and Astrazeneca on how to improve safety
Accelerate the development of therapeutics utilizing CRISPR and discover the clinical applications that are being studied with insights and data from Intellia Therapeutics, and Graphite Bio
Investigate novel Cas variants and understand how novel Cas proteins that optimize specificity and efficacy of gene editing will be vital to bringing CRISPR successfully into the clinic with Arbor Biotech and Harvard Medical School

To know more about CRISPR 2.0 Summit please click here.

SMi’s Aseptic Processing Conference
2021-09-20 - 2021-09-21 | Copthorne Tara Hotel, London, UK – (Virtual Attendance Option Available)
Sponsored by: Innerspace, Solo Containment and STERIS
Co-Chairs: Richard Denk, Senior Consultant Aseptic Processing and Containment, SKAN AG
James Drinkwater, Head of Aseptic Processing and Containment Special Interest Group, PHSS and Head of GMP Compliance, F Ziel GmbH
Exploring Effective Strategies and New Regulations for Compliant Pharmaceutical Manufacturing
The aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs, pragmatic barrier system applications, adaptability and modularity in fill finish, robotics and automation, small and agile product manufacturing, just to name a few. In 2018, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027, with a CAGR growth of 9.18%.
The industry is ever changing and with the advent of innovative therapeutics taking hold, regulators and industry leaders are prompted to take proactive approaches to get treatments to patients faster.
Join us to explore novel and developing technologies that tackle the most pressing challenges and push innovation in the world of aseptic processing and sterile manufacturing.
Event Hashtag: #SMiAseptic
Key Highlights Include:

Discuss the revisions and the impact of Annex 1 on aseptic manufacturing with AstraZeneca
Listen to a field report on the implementation of a global contamination control program with Takeda
Explore the applications of rapid micro methods in the manufacture of sterile products with AbbVie
Discover a Risk Based Approach to Cleaning and Disinfection with STERIS
Delve into case studies of competence in global aseptic manufacturing with Fresenius Kabi
Uncover the journey of Isolation Technology in a large Biotech pharmaceutical plant with Eli Lilly

Who Should Attend?

Validation Managers
Senior Microbiologists
Senior QA’s and QC’s
Quality Control Managers
Heads of GMP Compliance
Quality Assurance Experts
Technical Operations Leads
Leaders in Sterility Assurance
Cleanroom Managers
Regulatory Affairs Managers
Production Managers
Quality Systems Managers
Heads of Quality Compliance
Process Leaders
Senior Auditors
Bioprocess Research & Development

PLUS – Post-Conference Workshop on…
Contamination Control Measures in Good Manufacturing Practice (GMP) Applied to Aseptic Processing
Workshop Leaders: James Drinkwater, Head of Aseptic Processing and Containment Special Interest Group, PHSS and Head of GMP Compliance, F Ziel GmbH Kevin Jenkins, Consultant, Quality Excellence Consulting

3rd Annual RAS–Targeted Drug Development Summit
2021-09-21 - 2021-09-23 | Digital Event, EDT
As 2021 marks a major milestone for RAS therapeutics, with the first ever KRAS targeted therapy receiving FDA approval, the once undruggable RAS family of proteins is no longer impossible to crack. With this significant industry shift, this community will no doubt continue going from strength to strength and the future looks bright for future development of RAS targeted therapies that safely, effectively, and selectively drug all RAS driven cancers beyond those caused by G12C mutation.

The 3rd Annual RAS Targeted Drug Development Summit is returning once again this September to reunite the biggest community of thought leaders and experts in Oncology, Cancer Therapeutics and Clinical Development to discuss robust monotherapies or combination strategies capable of specifically targeting different RAS-mutant cancer cells with less toxicity to enhance the impact of RAS therapies against all RAS driven cancers beyond lung.
Via the latest preclinical, translational and clinical development data-driven case studies from academic and industry pioneers, the 3rd RAS Targeted Drug Development Summit is your only comprehensive roadmap to addressing unique challenges and future directions of finally drugging all RAS mutations and associated targets with novel modalities and next generation combination therapies.
Incorporating tracks taking a deep dive into accelerating emerging modalities, validating robust combination strategies and advancing clinical development, this is your opportunity to gain extensive strategic and scientific information enabling you to solve the exact challenges you’re encountering to support development of safe and effective next generation RAS targeted therapies.
To know more about 3rd Annual RAS–Targeted Drug Development Summit please click here.

4th International Cannabinoid Derived Pharmaceuticals Summit
2021-09-21 - 2021-09-23 | Aloft Boston Seaport District, 401-403 D St, Boston, MA, 02210, United States
The Cannabinoid Derived Pharmaceuticals Summit is the world’s largest conference devoted exclusively to the production of CDPs for medical conditions using FDA/EMA approval pathways. The 2021 agenda will focus on clinical trial design and commercialization, target biology and pharmacology, GMP-compliant product formulation, drug delivery, and managing the changing regulatory environment (particularly in light of new policies from the US government administration).

The Three-day Program Spans:

A brand-new section dedicated to building a robust clinical strategy will equip you with the knowledge that gave world leading cannabinoid drug developers a commercial and clinical edge in the race to approval
Analyzing new discoveries in cannabinoid pharmacology and ECS biology to identify new opportunities
Discussion of vital IP and investment topics for a comprehensive update on the health of the industry
Preparation for post-approval through exploration of key issues relating to commercialization and supply chain management of cannabinoid medicine products and APIs

The 4th International Cannabinoid-Derived Pharmaceuticals Summit brings together drug developers working on the complex and difficult production of both plant-based and synthetic endocannabinoid system modulators. An elite panel of speakers will discuss important topics such as rigorous clinical trial data exchange, guided discussion, and industry networking.
Meet face-to-face with decision makers from the likes of Greenwich Biosciences, ACHEM, Cannvalate, Cannabics Pharmaceuticals, Oxford Cannabinoid Technologies and more at the first physical cannabinoid conference of the year.
To know more about 4th International Cannabinoid Derived Pharmaceuticals Summit please click here.

2nd Gene Therapy for Ophthalmic Disorders
2021-09-21 - 2021-09-23 | Digital Event
Returning in September as a digital event, the 2nd Gene Therapy for Ophthalmic Disorders meeting will target the industry’s translational challenges in targeting both rare and common ophthalmic disorders including wet AMD, dry AMD, DME, IRDs and more.
Discover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from the likes of GenSight Biologics, Biogen, Gyroscope Therapeutics, Novartis, Horama and REGENXBIO

Join 150+ fellow industry attendees from discovery, preclinical and clinical backgrounds, to learn lessons in rare disorders and seize the opportunity in common ophthalmic disorders.
This meeting will allow you to:

Hear the latest data in ocular gene therapy immunogenicity and vector strategies to overcome Inflammation
Highlight optogenetics and gene agnostic approaches from SparingVision, GenSight Biologics and Bionic Sight
Learn how Clearside Biomedical are progressing suprachoroidal delivery with the potential to minimize invasive surgical procedures
Discuss the clinical progress with different administration routes to the eye with clinical experience from REGENXBIO
Gain key vector insights from Eyevensys, who are developing non-viral vectors to minimize immune response and increase likelihood or re-dosing
Explore the realities of clinical trial design to meet regulatory expectations throughout a program, with insights from Gensight Biologics
Hear pharma representatives discuss the opportunities and realities of collaborating with biotechs, with experience from Novartis
Hear from a Luxturna patient to understand their first-hand experience of receiving the therapy, and have an opportunity to ask them your questions
Highlighting progress in ASOs for ophthalmic disorders for a deeper understanding of the ophthalmic landscape with data from ProQR

View the event guide here for full agenda details and the expert speaker faculty.

6th Annual PREDiCT: 3D Tissue Models Summit
2021-09-21 - 2021-09-23 | The Colonnade Boston – 120 Huntington Avenue, Boston, MA 02116, United States
The 6th PREDiCT: 3D Tissue Models Summit is the only industry-led summit focusing on real-world application of 3D models in drug discovery and development. With 25+ experts sharing fresh case studies on 3D Tissue Models data, how to foster technology maturation, and lower costs to drive industrial adoption, this is a conversation not to miss.

Returning as an in-person meeting in Boston, our 2021 program will delve further into advanced 3D organoids, organ-on-chips, microphysiological systems (MPS), and tissue engineering – from oncology to other therapeutic areas – not only in preclinical safety and toxicology models but also back to translation in clinical Ph1 for biomarkers and patient stratification for better Ph2 design.
Join 80+ experts on scientific and real-world application dialogues with the likes of FDA, GSK, Takeda, MIT, and many more, sharing their journeys and lessons learned with complex in vitro models, compared with conventional in vivo and 2D cell studies.
To find out more and view the 2021 speaker line-up, download the full event guide.
Book with confidence! – As the world begins to re-open and in-person events become a reality, join us again in Boston for the first time in more than a year, to learn expert insights and generate quality industry connections in a face-to-face capacity. See how we’ll ensure your safety here.

Oligonucleotide Therapeutics and Delivery Conference
2021-09-22 - 2021-09-23 | Holiday Inn Kensington Forum, London, London, United Kingdom
On the way to maximising the potential of oligo-based medicine
Oligonucleotide therapeutics – the emerging medicine class – are harnessing the therapeutic benefit of targeting genetic material via antisense, mRNA, RNAi, saRNA and siRNA. Their market growth: CAGR of 13.7% projected to reach USD 8.2 billion by 2024 is driven by their potential to provide more efficacious and less toxic alternatives to small molecules. They bring about the ability to affect targets that have been considered “non-draggable”. Heavy investments in oligonucleotide therapeutic discovery have created an emerging market need for drug delivery technologies.

SMi’s inaugural Oligonucleotide Therapeutics and Delivery conference is here to keep you updated. By bringing together leading representatives of pharmaceutical, biotechnology and academic institutions, the 2-day conference will provide first-hand information on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY. From optimizing particle size to choosing the right nanocarrier systems, the conference will address delivery to non-hepatocyte cells such as cancerous tissues and overview the most successful platforms. Discussions will be centered around improving targeted therapy uniting the field’s biggest players to share their opinions.
Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.
Benefits of attending:

Gain first-hand insight into oligonucleotide therapy clinical success up to date for improving development of novel agents in your pipeline
Listen to case studies presenting the latest candidates undergoing pre-clinical and clinical research
Deepen your understanding of crucial delivery methods and available platforms for non-hepatocytic delivery
Collaborate with members of the oligonucleotide community leading pharmaceutical, biotechnology and academic representatives to maximise future opportunities

Plus, an interactive half day pre-conference workshop on Oligonucleotide drug discovery: Target selection, delivery, molecular design and lead identification.
CHAIR FOR 2021:

Nagy Habib, Head of HBP Surgery, Imperial College London and Co-Founder, Head CNN of R&D and Chief Medical Officer, Mina Therapeutics

SCIENTIFIC ADVISORY BOARD 2021:

Ekkehard Leberer, Senior Director, Alliance Management, Sanofi
Mark Edbrooke, Independent Consultant
Troels Koch, Chief Technology Officer, SVP Science and Technology, Inexos Therapeutics
Sudhir Agrawal, Founder and President, ARNAY Sciences and Idera Pharma and Professor, University of Massachusetts Medical School

FEATURED 2021 SPEAKERS INCLUDE:

David Evans, Chief Scientific Officer, Sirnaomics
Alexey Wolfson, CEO, Advirna
Stefan Vonhoff, VP Chemistry & Manufacturing, NOXXON Pharma
Vera Brinks, Director Pharmaceutics, ProQR Therapeutics
Matthew Catley, Research Director, MiNa Therapeutics
Steve Pascolo, Founder and CEO, Miescher Pharma

Who should attend:

RNA Biology/Discovery
Novel Therapeutic Modalities
Innovation Technologies
C-level Scientific Executives
Formulation and Drug Delivery
Clinical Research and Development
Cell Biology

Additional Contact Info:
T: +44 (0)20 7827 6088
E: hsidhu@smi-online.co.uk
LinkedIn: @SMi Pharma
Twitter: #SMiOligonucleotides

Aseptic Processing Conference
2021-09-22 - 2021-09-23 | COPTHORNE TARA HOTEL, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
SMi’s Aseptic Processing Conference
Exploring aseptic facility design and operation to implement agile contamination control strategies Conference: 22 – 23 September 2021
Location: Copthorne Tara Hotel, London, UK
Website: http://www.asepticprocessing.co.uk/PJWL
SPONSORED BY: Innerspace & Steris
CHAIRED BY: James Drinkwater, Head of Aseptic Processing & Containment Special Interest Group, PHSS and Richard Denk, DACH Affiliate, ISPE

The aseptic processing industry has seen many changes during its progression towards the 21st century. With advances in innovative therapeutic manufacturing such as ATMPs, pragmatic barrier system applications, adaptability and modularity in fill finish, robotics and automation, small and agile product manufacturing, just to name a few. In 2018, the global aseptic processing market was valued over $56 trillion and is estimated to increase in net revenue upwards $124 trillion by 2027, with a CAGR growth of 9.18%.
The industry is ever changing and with the advent of innovative therapeutics taking hold, regulators and industry leaders are prompted to take proactive approaches to get treatments to patients faster.
Join us to explore novel and developing technologies that tackle the most pressing challenges and push innovation in the world of aseptic processing and sterile manufacturing.
Event Hashtag: #SMiAseptic
At the Aseptic Processing Conference, you will gain insight into:
Featured 2021 Speakers include:

Scott Nichols, Microbiologist, FDA
Serena Ambrosini, Sterile Manufacturing Manager, AstraZeneca
Jim Polarine, Senior Technical Service Manager, Steris Corporation
Di Morris, Audit Manager CAG, GSK
Stephen Yang, Director, Global Sterile Validation COE, Merck
Kevin Jenkins, Consultant, Quality Excellence Consulting

KEY HIGHLIGHTS INCLUDE FOR 2021

Discuss the latest regulatory updates in the industry from leading regulatory bodies
Listen to global case studies in aseptic competence from companies pioneering in the pharmaceutical industry
Explore advances in ATMP facility design that are revolutionising aseptic manufacturing
Delve into the newest contamination control technologies from VHP disinfection to fully automated pipelines

PLUS – Pre-conference workshop on…
Contamination control measures in Good Manufacturing Practice (GMP) applied to Aseptic processing
Workshop leaders: James Drinkwater, Head of Aseptic Processing and Containment Special Interest Group, PHSS and Kevin Jenkins, Consultant, Quality Excellence Consulting
View the brochure and to download visit http://www.asepticprocessing.co.uk/PJWL

4th Annual Neuropsychiatric Drug Development Summit
2021-09-28 - 2021-09-30 | Online
This last year has been a brutal reminder as to how crucial it is that we tackle the impending global mental health crisis and find a path towards successful neuropsychiatric drug development.
We are proud to be the industry’s definitive and unrivalled forum focused on encapsulating the recent clinical advances across this extremely arduous field. This timely meeting provides a much-needed platform for industry and academic thought leaders to:

Investigate new treatment paradigms to support schizophrenia patients with Sunovion, Merck, Cerevel and BioXcel
Strive for useful biomarkers in clinical practice and explore novel electrophysiological biomarkers of synaptic plasticity in humans with Lundbeck, Daniel Javitt and Takeda
Hear patient-centric approaches towards developing efficacious and engaging digital therapeutics with Thomas Insel, MindMed
Decipher the recent hype in psychedelics by evaluating new data emerging on hallucinogens with Psilera, MAPS, Eleusis, ATAI and Perception Neuroscience
Discover the major advances in understanding neuroinflammation across CNS indications and how can we use this to help us further understand psychiatric conditions with Johnson & Johnson and Inmune Bio

Don’t miss out and join over 80 of your peers at this timely event to take a step closer towards your ambitious goal of drastically improving the lives of individuals living with neuropsychiatric disorders.
To know more about 4th Annual Neuropsychiatric Drug Development Summit please click here.

12th Annual World Bispecific Summit
2021-09-29 - 2021-10-01 | Virtual Event
The 12th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery, translational, and manufacturing challenges faced in the bispecific field. Whatever your role and interest, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients.

Discover who the 45+ expert speakers are, and the topics they will examine, including how:

OSE Immunotherapeutics is pioneering their unique platform BiCKI a bispecific platform optimized for the development and manufacturing of bispecific cytokine fusion proteins
GT Biopharma and Light Chain Bioscience are showcasing the next generation of innate cell engagers for the treatment of solid tumors
Merus, Pfizer, and Innate Pharma are expanding the boundaries of biotherapeutics with tri-specific and multi-specific antibodies
Genentech, Pfizer, and City of Hope are discussing approaches to reduce on-target off-tumor toxicities including dosing strategies in liquid and solid tumor indications
Xencor, Harbour Biomed, and Harpoon Therapeutics will discuss their unique platforms and CMC strategies for scale-up and production
IGM Biosciences and MacroGenics will evaluate biomarker strategies for bispecific candidates during clinical development

To know more about 12th Annual World Bispecific Summit please click here.

11th World Clinical Biomarkers & CDx Summit
2021-09-29 - 2021-09-30 | Digital
Accelerating R&D to Commercialization by Leveraging Predictive Biomarkers & Clinical Diagnostics Evidence for Best Patient Outcomes in Target Populations
The 11th World Clinical Biomarkers & CDx Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic, their clinical validation and later commercialization with a CDx.
With over half of drugs approved by the FDA now supported by a biomarker and as new CDx collaborations are announced on an almost weekly basis, demand for diagnostic tools enabling earlier, more precise, therapeutic interventions is at an all time high. Join with 650+ key stakeholders across biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market.
Across 2 days of comprehensive content, 65+ global expert speakers will share fresh data paired with inspiring stories from innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine for heterogeneous patient populations.
With 3-tracks addressing the entire lifecycle of biomarker-driven drug development, explore biomarkers and Dx movement within bioanalytical analysis, AI/ML application, data sharing and the regulatory and payer landscape. Covering immune-oncology, neurodegenerative, metabolic, autoimmune and rare indications, gain a diverse picture of today’s expanding personalized medicine ecosystem.
This is your unmissable event, bringing you the tools, insights and techniques to design a clinically robust biomarker and commercially competitive CDx!
To know more visit: https://world-cdx.com/

9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference (EST TIME ZONE)
2021-10-05 - 2021-10-08 | Virtual Event
Leveraging next gen technologies beyond conventional biomarker drug discovery
The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.
The 9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference scheduled to be held from 5th – 8th October 2020 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.
This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.
Event Website: https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/
Registration link: https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register

2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit
2021-10-05 - 2021-10-07 | Digital Event | EST
The 2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit is the only event uniting key B&T cell decision-makers to advance the therapeutic future of autoimmune diseases.
Join this community of 60+ pioneers to aid discovery, development, optimization and strategy for a new generation of treatment within this area of vastly unmet clinical need.
This cross-disciplinary program featuring keynote talks from 32+ clinical KOLs from large pharma, biotech and academia, will give you insight into the full therapeutic opportunity of drug candidates against various plasma, B and T cell targets.
Unite with other B & T cell researchers as we look to optimize therapeutic targeting of the bidirectional interactions between B and T cells, B cell functions (autoantibody production, antigen presentation, T cell help & cytokine production) and autoreactive T cells contribution to autoimmune pathogenesis and disease progression.
View our full event guide to see our complete speaker line-up, latest agenda, and workshop details. https://ter.li/0zk3pp
Key Discussions you Can’t Afford to Miss:

Delve into the exciting world of cell engineering and novel targets for rare autoimmune diseases and what they mean for the field with Abcuro, Polyneuron, Apitope, NYSCF, UTHSC & Cabaletta Bio
Discover the novel and promising candidates targeting B cell development factors and related cytokines with Eli Lilly & Co, UCL, Kyverna, Immunic AG, Nurix & GSK
Uncover the pathologies and targets for the B & T cell co-stimulatory pathways and novel mechanisms in disrupting collaboration with Artax Bio, Cytocom, Horizon, AltruBio & Novartis
Explore targets, considerations and strategy for targeting autoantibody producing plasma cells, organ specific and systemic diseases with UCB, Provention Bio, IM Therapeutics & Biogen
Optimize application and patient outlook through combination strategies, early detection and emerging biomarkers and look to next steps in your drug development with Oklahoma Medical Research Foundation, Bristol-Myers Squibb & Eli Lilly & Co

Find out more https://ter.li/0zk3pp

SMi's 2nd Next Generation Pharmaceutical Cleanroom Conference
2021-10-06 - 2021-10-07 | Copthorne Tara Hotel, London, United Kingdom
SPONSORED BY: Elis Cleanroom and Innerspace
CHAIRED BY: Matts Ramstorp, CEO & Founder, BioTekPro
Addressing the Microbiological Aspects in Cleanroom Design & Engineering
SMi Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Europe Conference. An event that focuses on cleanroom technology in the pharmaceutical industry, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point.
This one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals, biologicals, and cleanroom industry experts to explore hot topics within cleanroom design and engineering, best practices and regulation, environmental and contamination control, and pharmaceutical microbiology.

In 2025, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals, technological advancements in cleanrooms, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market.
This event will look in-depth at the significant change that the cleanroom industry is going through. From the new operating practices that keep the product as sterile as possible, to the developments in technology that are enabling this to happen. Whether through robotics, automated disinfection, or data driven environmental monitoring- this conference will highlight the developments that are fundamentally changing the industry.
Event Hashtag: #SMiCleanroom
HIGHLIGHTS FOR 2021:

UNDERSTAND the current regulatory landscape from both designer and regulator perspectives
EXPLORE the innovations in technology that are shaping the next generation of cleanroom facilities
DETERMINE the best approaches to cleanroom design and operation from global case studies
GAIN insight into the latest developments in cleanroom protocol from leading industry experts

FEATURED 2021 SPEAKERS INCLUDE:

Tim Sandle, Head of Microbiology and Sterility Assurance, Bio Products Laboratory Ltd
Conor Murray, Principal, Irish Cleanroom Society
Joseph McCall, Associate Director, QA Technical Service, ADMA Biologics
Benoît Ramond, Head of Microbiology & Sterile Technology, Sanofi
Walid El Azab, Senior Manager Technical Services, STERIS
Dawn Tavalsky, Senior Director Global Sterility Assurance, Sanofi Pasteur
Patrizia Muscas, QA & Sterility Assurance, Eli Lilly
Christine Arbesser-Rastburg, Director, Head of Global Microbiology, Takeda

WHO SHOULD ATTEND:
Senior Micro Manager, QC Manager, Quality Director, Clean Room Design Managers, Design, Qualify and Testing – Clean Room (across the board), Head of Clean Room Technologies, Head of Compounding Pharmacies, Head of Clinical Drug Products, Head of Clinical Medical Device
ADDED VALUE – 2 x Pre-Conference Workshops on…
Workshop A – 08.30 – 12.30: Applying ISO and EN Standards to Non-Viable and Viable EM in the context of the new Annex 1 guidance and a CCS in GMP Cleanrooms
Workshop Leader: Conor Murray, Principal, Irish Cleanroom Society
Workshop B – 13.30 – 17.30: Cleanroom Garments – need, function and use
Workshop Leader: Matts Ramstorp, CEO & Founder, BioTekPro
View the brochure and to download visit www.cleanroomtechnology.co.uk/PJwl

Wearable Injectors and Connected Devices Conference
2021-10-18 - 2021-10-19 | Copthorne Tara Hotel, Scarsdale Place, Kensington, London, W8 5SY, United Kingdom
The latest innovations in digital health and on-body drug delivery for the pharmaceutical industry
SMi’s 2nd annual Wearable Injectors and Connected Devices Conference will explore real world case studies of on-body device design and development for large volume delivery while engaging in the latest digital applications for wearable devices with industry case studies from pharma thought leaders. The conference will consider key developments in the wearable injectors field, including the enhanced demand for on-body injectors and digitalised health as the pandemic highlights the need for self-administered at-home care, managing sustainability in the field, and opportunities for development in oncology.

Key regulatory updates including guidance on MDR requirements and the impact of Brexit on data collection will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts.
This two-day agenda offers you peer-to-peer networking with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.
We look forward to welcoming you to the conference in October.
For more information and to register: www.wearable-injectors.co.uk/pjwl
BENEFITS OF ATTENDING:

Gain insight into developments in wearable devices in clinical trials and adapting to decentralised trials during the pandemic
Explore design strategies for connectivity and digital health with sessions from Novartis and Bayer
Hear key regulatory updates from regulatory and notified bodies including TÜV SÜD
Discover advances in device design for large volume delivery via on-body injectors
Explore and benchmark against industry developments through case studies and real-world examples in device development for on-body injectors

Plus, two interactive half-day workshops – Wednesday 20th October 2021
A: Cross company collaboration to develop digital therapeutic solutions using connected devices
Workshop Leader:
Digby Harris, Global Procurement Lead – Digital Therapeutics, AstraZeneca
B: Optimising Patient Engagement and Creating Novel Company Value through Digital Technologies
Workshop Leaders:
Alex Gilbert, Digital Medicine, Huma
Early-Bird Rates

BOOK BY JUNE 30TH TO SAVE £200
BOOK BY AUGUST 31ST TO SAVE £100

SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #SMiWearables
LinkedIn: follow our company page – search ‘SMi Pharma’

2nd Annual Dry-AMD Therapeutic Development Summit
2021-10-19 - 2021-10-21 | Online
Returning for its 2nd year as the world’s leading industry forum, Dry-AMD Therapeutic Development establishes meaningful clinical endpoints using the latest diagnostic imaging techniques to prove therapeutic safety and efficacy in specific patient populations.
In the context of unprecedented Phase III progress, and as new investigational pharmacological agents enter the clinic, Dry-AMD Therapeutic Development will deliver a greater breadth and depth of technical content than any other meeting in this field with 3 days and 2 tracks of dedicated content.

Uniting large pharma, biotech and academic KOLs with a reimagined agenda, this year’s meeting devotes specific content to the unique discovery, pre-clinical, translational, clinical development and commercialization challenges encountered within the dry-AMD space. Ensuring that whatever your role in the field, you will leave with tangible actions to implement into your strategy and pipeline, to translate the promise of dry AMD therapies into a reality for patients.
Join the 200+ expert community, as they unite under a common goal of accelerating the approval of next generation therapies for this progressive eye disease.
To know more about Dry-AMD Therapeutics Summit please click here.

Medical Wearables for Biosensors USA Conference 2021
2021-10-25 - 2021-10-26 | Sheraton Boston Hotel, Boston, USA (Virtual Attendance Option Available)
Exploring therapeutic applications of connected on-body devices
The global wearable biosensors market is a rapidly expanding industry with increasingly growing potential for applications in healthcare and technological advances. With potential in remote patient monitoring, diagnosis and detection of disease, biosensors and wearable devices are gaining substantial interest due to their opportunities to offer continuous and reliable physiological information allowing for better support of patient needs.
With that in mind, SMi is proud to present the Designing Biosensors for Medical Wearables Conference, taking place on the 25th – 26th October 2021 in Boston.

BENEFITS OF ATTENDING:

Engage in case studies from leading experts on wearable devices for remote diagnostics and patient monitoring
Explore how industry is using on-body biosensors for a patient centric-approach to therapeutics
Delve into the regulatory landscape of digital health and data management with regulatory body and leading expert addresses
Uncover the evolving research into smart vaccines for COVID-19 and accelerating accessibility of new wearable technologies

Register online: www.biosensors-medical-wear.com/pjwl
Plus, two interactive half-day workshops – Wednesday 27th October 2021
A: Digital Integration within Clinical Trials
Workshop Leaders:
Gary McNamara, Senior Delivery Manager, Aparito
Daniel Lewi, Head of Business Development, Aparito
B: Energy Harvesting Systems for Body-Worn Sensors
Workshop Leaders:
Veena Misra, Distinguished Professor, Director, NSF Center for Advanced
Self-Powered Systems of Integrated Sensors and Technologies (ASSIST)
Early-Bird Rates

BOOK BY JUNE 30TH TO SAVE $200
BOOK BY AUGUST 31ST TO SAVE $100

SOCIAL MEDIA HANDLES
Twitter: @SMiPharm #SMiBiosensors
LinkedIn: follow our company page – search ‘SMi Pharma’

4th Targeted Protein Degradation Summit
2021-10-26 - 2021-10-29 | Digital Event, EDT
As the most comprehensive, industry-focused and ‘must-attend’ event in the field, the 4th Targeted Protein Degradation Summit returns to once again explore the latest approaches, perspectives, and data-drive case studies that will continue to advance PROTACs, molecular glues, and other degrader modalities towards clinical success.
With 70+ world-class speakers and over 500 senior attendees from around the globe, join the largest community of protein degradation experts for a deep dive into clinical development progress, lessons learnt and novel strategies to develop safe, selective and effective PROTACs, molecular glues, lysosomal degradation, autophagy-mediated degraders as well as uncovering novel degrader modalities and approaches for oncology and beyond.
Key Highlights:

Evaluate the exclusive updates of ongoing clinical trials to accelerate towards the first clinically approved therapy with insights from Kymera Therapeutics, Arvinas, Nurix Therapeutics & Bristol Myers Squibb
Deep dive into the methodologies of enhancing target engagement by improving target specificity, uncovering strategies to find novel ligases and modelling of covalency to develop next generation degraders with insights from Eli Lilly, FogPharma, GSK & Janssen
Review the plethora of disease indications that are being targeted by PROTACs and molecular glues including Alzheimers, Parkinsons, COVID-19 and AML with insights from Bristol Myers Squibb, Progenra & Origami Therapeutics
Explore the different approaches to penetrating the blood brain barrier, comparing and contrasting the discovery, development and optimization of PROTACs and molecular glues for neurodegenerative indications with insights from C4 Therapeutics & Progenra
Outline the core mechanisms of PROTAC resistance and the approaches to overcoming this to successfully progress through preclinical and clinical studies with insights from University of Dundee, Ranok Therapeutics & Captor Therapeutics

To know more about 4th Targeted Protein Degradation Summit please click here.

5th Complement-based Drug Development Summit
2021-10-26 - 2021-10-28 | Virtual/Online
Discover the Intricacies of Complement Pathways to Accelerate Clinical Validation & Maximize Complement-Targeting in the Pan-Disease Setting
Built with Alexion, Apellis and Annexon, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industry dedicated forum to maximize complement-targeting in the pan-disease setting.
With pivotal clinical readouts poised to be released in 2021, this year’s summit will once again unite thought leaders in complement-based drug development.

Expect to be involved in interactive discussions on:

How dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5
Preclinical and clinical pipeline progress of diverse drug modalities, including gene therapy approaches, small molecule inhibitors, antibodies, protease inhibitors, nucleic acids & more!
Leveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics
Addressing clinical challenges of complement-targeted therapeutic sequencing, combinations and timing of administration
Expanding the clinical utility of complement inhibitors across rare diseases, as well as autoimmune, ophthalmic, neurological and cancer settings

New for this year, you’ll have a two-tracked agenda with more speakers, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets!
To know more about 5th Complement-based Drug Development Summit please click here.

6th Annual Neoantigen Based Therapies US Summit 2021
2021-10-26 - 2021-10-28 | Digital Event
Your Comprehensive End-to-End Guide to Transforming the Clinical Development of Cell & Vaccine Based Neoantigen Therapies
The growth and comeback of the neoantigen space has resulted in an abundance of new data, innovative insights and valuable lessons learned on how to drive meaningful clinical responses, all of which will be shared at the 6th Neoantigen Based Therapies US Summit.
Exploring the potential of shared neoantigens vs. personalized neoantigens and optimizing the selection and identification of the best and most immunogenic neoantigens, the world’s leaders from the likes for BioNTech, Gritstone, Advaxis, Genocea, Treos Bio and many more will gather at the only 3-day summit focused on the exploding field of Neoantigen based Therapies.
Join over 100 experts to discuss what the optimal control, clinical and combination trial designs should look like, advances in accurate and robust validation assays, and explore how we can manufacture effectively and at scale both shared and personalized neoantigen based therapies.
Leave this meeting equipped with new collaborations across pharma, biotech and academia, and learn how to supercharge vaccine and cell immunotherapies for solid tumors and beyond.
To know more about 6th Annual Neoantigen Based Therapies US Summit 2021 please click here.

2nd Supply Chain and Logistics for Cell Therapies Summit
2021-10-26 - 2021-10-28 | Virtual Event | Eastern Time
At the virtual 2nd Supply Chain and Logistics for Cell Therapies Summit, your community will gather to network, share exclusive insights in case-study led sessions, and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale.
Implement robust, patient-centric supply chains for clinical to commercial readiness:

Build your supply strategyand manage risk and forecasting at scale by designing for growth
Maximize your cloud-based and integrated systems and hear the latest innovations in chain of identity

Manage materials, external manufacturing and facility design

Optimize patient care with best practice guidelines and integrated platforms:

Understand clinical requirementsand develop clinical strategies for seamless therapeutic delivery
Discuss and establish industry best practices and understand which standard practices can apply across a range of cell modalities

Maintain product quality at scale for seamless delivery of autologous and allogeneic therapies:

Optimize front-end processes and develop patient care organisations
Discuss quality control and site audits to ensure best standard of care and product quality

Find out more >>> https://ter.li/mt5mh1

9th Advanced RWE Applications in Pharma
2021-10-26 - 2021-10-28 | Virtual
Real-world evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real world into their development programs, drug developers can now improve their clinical trial success by identifying and retaining suitable patients through increased patient stratification.
These are exciting times to reunite at the 9th Advanced Real-World Evidence Applications in Pharma to discuss the efforts to advance real-world evidence’s effective generation and utilization.
The stage is set for a collaborative discussion platform bringing together you and other stakeholders from functions across clinical development, RWE, RWD, Data Science, Regulatory Affairs, Medical Affairs, HEOR, and many more!
Join us in October to overcome critical challenges in generating and implementing real-world evidence to enhance clinical R&D, support regulatory submission and decision-making, and ultimately drive commercial success.
Click here to download the event guide for the full agenda

What’s New in 2021?
2020 was an exciting year for real-world data (RWD) and real-world evidence (RWE) experts within pharma and biotech. The FDA’s high-profile acceptance of RWD as part of their review for COVID-19 treatments and vaccines for emergency use authorization was a big moment for the industry. This is now energizing RWD and RWE into R&D and clinical activities – expediting novel treatments for patients and substantially reducing drug developers’ R&D spend.
However, major questions still need answers urgently. The 9th Advanced Real-World Evidence Applications in Pharma will return in October 2021 to delve into the core industry challenges, including:

Assessing the global regulatory environment for future RWE application
Advanced data acquisition and analytics to enable your R&D and clinically informed decision making
Leverage RWE in your clinical activities – from patient selection to synthetic trial arm
How to create a robust, regulatory-compliant RWE framework and data package for your successful IND filing
Maximizing your product lifecycle through a comprehensive observational data program
Establishing pre-competitive collaboration to deepen your understanding of diseases, offering patients a personalized and effective treatment through RWE & RWD

Book now to save up to $750

Protein Engineering Global USA
2021-10-27 - 2021-10-28 | Holiday inn San Jose- Silicon Valley, 1350 North 1st Street, San Jose, CA, 95112, United States
The series brings together a global audience and global lineup of biocatalyst and protein modifications specialists to share how to implement the new technologies. With the applications growing across pharmaceutical, flavour & fragrance, consumer goods, food & beverage and agrochemical sectors, we have created a protein and enzyme engineering platform that will allow the community to improve capabilities to industrialize sustainable enzyme products and increase product efficiency globally.
Understand the challenges and requirements of the industry in their internal R&D projects to support scale-up processes, next-generation mutant library screening, or knowledge of machine learning and AI to optimize biocatalysts for industrial applications.
Expand your commercial opportunities and market growth by learning what new industry sectors are seeing the benefit of enzyme engineering to synthesize unprecedented molecules of interest and engage and network with these industries to form new third-party collaborations, allowing you to advance your market growth.
Demonstrate advancements in your service capabilities by actively promoting the work of your technical teams through bespoke webinar opportunities, presentations, and interactive discussion with the industry.
We are delighted to be hosting Protein Engineering Global 2 miles from San Jose International Airport SJC, and offer a special bedroom rate to the attendees of the Protein Engineering Congress:
$199 + tax per room per night – Please call +1 408-453-6200 and quote Kisaco research/Protein Engineering.
Download agenda: www.proteinengineeringglobal.com/

5th Antifibrotic Drug Development Summit - AFDD
2021-11-01 - 2021-11-03 | Digital Event
The 5th Antifibrotic Drug Development Summit will provide a unique opportunity to gain cross-discipline actionable insights into how the latest scientific research is being applied to fibrosis pipeline progress. Network with industry pioneers in hot areas of drug development, specifically IPF, NASH, scleroderma, IBD, ILD, CKD, and more to apply disease-specific lessons agnostically, and understand how the industry can achieve the crowning glory of pan-fibrosis antifibrotic drugs.
Unmissable Highlights for 2021:

Join the active discussion surrounding redefining approvable clinical endpoints with the FDA to enhance opportunities for creative clinical trial design and drive your clinical development
Engage with early initiatives to establish clinical development programs in IBD-associated fibrosis with Cleveland Clinic to kickstart your intestinal fibrosis pipeline as this grows in interest for biopharma
Investigate the buzz around reprogramming epithelial cells to promote tissue repair in fibrotic disorders with Genentech to understand new strategies for regenerative medicine and overcome mechanistic bottlenecks
Gain vital insights from Pfizer on how the industry can revolutionize the translatability of current disease models and collaboratively guide the creation of technologies that can better mimic human physiology
Embrace more successful clinical trial design with an enhanced focus on patient-reported outcomes with Novartis to identify precision medicine approaches, promote patient engagement, and discuss regulatory barriers to novel endpoints

Hear from 35+ industry heavyweights including Genentech, AstraZeneca, FDA, GSK, Boehringer Ingelheim, Pfizer, Takeda, and more to understand transformative mechanistic strategies for promoting tissue regeneration and repair, discover more robust predictive models to improve translatability; and assess emerging non-invasive biomarkers that identify early signs of efficacy and drive successful clinical trials.
To know more visit: https://ter.li/afddpjel

Gastrointestinal Cancer Drug Development Summit
2021-11-02 - 2021-11-04 | Digital Event | EST
The Gastrointestinal Cancer Drug Development Summit is the only biopharma-led conference dedicated to identifying and progressing therapeutic opportunities in targeted and immunotherapies, ADCs, and precision oncology to address the large unmet clinical need in GI cancers.
**This meeting is free-to-attend for drug developers, research institutions, and not-for-profit organizations**.
Register free to attend here: https://ter.li/t83wdr
This industry-dedicated meeting offers a comprehensive insight into developing optimal clinical programs for targeted, immune, and ADC therapies in these solid tumors. Join us and our 39+ expert speaker faculty as we navigate cancer heterogeneity and develop biomarker-driven enrichment strategies to direct better treatments to specific patient subsets and invest in rationale therapeutic combination approaches for this vastly unmet clinical need.
Whether your group is targeting microsatellite instable (MSI) and stable (MSS) CRC, a rare GI malignancy or treatment-resistant HCC, this unique forum is your opportunity to establish clinical collaborations, plan new combinatorial studies and assess how a future drug candidate can change the clinical landscape.
Explore the full conference guide here: https://ter.li/9m9m8u
**A “drug developer” or “researcher” must have a pipeline candidate and/or work for an academic institution, and must not provide solutions or services for a fee to any other company. All bookings under the drug developer/researcher category are subject to organizer approval.

2nd Applied Biocatalysis Summit
2021-11-03 - 2021-11-04 | Digital Event
Understanding the most recent developments in enzyme-catalyzed processes, computational technologies, and cutting-edge methodologies in biocatalytic cascade reactions is key to help the API and chemical industries apply biocatalysis more effectively.
Specifically designed alongside experts in the field, this conference will delve into the key technology, enzyme design, manufacturing, and scale-up challenges that must be overcome to achieve the commercial promise of biocatalysis.
Join us online for 2 days of insightful content, live Q&As, and 2+ hours of networking, as we bring together medication developers, chemical manufacturers, agriculturists, and researchers working on the complex and difficult development of biocatalyst technology.
This is your comprehensive virtual guide to defining your commercial potential of implementing biocatalysis methods in 2021.
To know more visit: https://ter.li/s09i3k

LEAP TA Life Sciences
2021-11-08 - 2021-11-10 | Digital Event
LEAP TA: Life Sciences is a unique open platform for the boldest talent leaders in the industry to engage in genuinely disruptive dialogues. Meet 80+ of your peers to rethink your recruitment approach, allowing you to find better people faster in an increasingly competitive talent market.
Taking part in this live online event will help you redefine your processes in an uncertain world, and successfully navigate the new normal operating environment.
This is your opportunity to fill the gap between reading an article and hiring an external consultant to help you solve your own recruitment challenges for the short, medium, and long term.
To know more visit: https://ter.li/od0sc4
